The past few years have been challenging for the biotech.

Now, it’s worth noting Stock Advisor’s total average return is 892 % — a market-crushing outperformance compared to 194% for ...

A sales partner offered a ray of hope that this company couldn't for itself.

Cathie Wood's ARK Invest bought Recursion Pharmaceuticals and CRISPR Therapeutics while selling PagerDuty, Teradyne, and Salesforce on8, 2026.

2026 could be a big year for this company.

In this article, we will take a look at the Top 10 CRISPR Stocks to Buy Now. Innovation is a hallmark of the biopharmaceutical sector, which is fueled by the demand for novel therapies to address ...

CRISPR biosensors are transforming healthcare by detecting biomarkers at attomolar sensitivity, enabling real-time health monitoring through wearable patches and implantable sensors. They continuously ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the 10 Stocks Going Wild. Crispr Therapeutics rallied for a second day on Wednesday, adding 9.6 percent to close at $60.08 apiece, tracking the rally in ...

Cathie Wood aims to identify innovators and invest in them early in their stories. Wood has been regularly adding to her position in this stock, and it’s one of her top holdings. 10 stocks we like ...

The global biotechnology market is expected to grow at a rate of 13-15% over the next five years. Key drivers of this growth ...